|
IVR101/2 – Topical Antifungal Onychomychosis
Indication
Onychomycosis is a fungal infection that causes toenails and sometimes
fingernails to discolor, thicken, and disfigure. Aging of the
population, ill-vented shoes, locker room exposure and different strains
of fungi are believed to contribute to increased prevalence of
onychomycosis, especially in younger adults. Onychomycosis starts as a
cosmetic concern. Without proper treatment, however, the nails can become so thick that they press against the inside of footwear, causing
pain and irritation. In certain patients onychomycosis can act as a
portal for bacterial infections.
Onychomycosis is treated by prescription doses of either topical or oral
medications. Because nails grow slowly, it takes up to a year for the
nail to regain a healthy, clear, thin appearance with either topical or
oral treatments when successful. Additionally, patients frequently
suffer reoccurrences of the infection.
Topical treatments consist of daily applications of a nail lacquer for a
period of several months. The fungicidal active ingredients in theses
lacquers must pass through the nail to reach the targeted fungus.
Lacquers, however, tend to quickly dry on the surface of the nail and
very small amounts of the active ingredient actually reach the fungus.
Lacquers also build up on the nail surface and at intervals must be
removed using chemical solvents before treatment can continue. Organic
materials in the lacquer may also irritate surrounding skin.
Consequently, the success of treatment of onychomycosis with nail
lacquers has been marginal for physicians and disappointing to patients.
Oral medications for the treatment of onychomycosis are also
administered over a period of several months. These medications have a
higher success rates than topical medications but are not recommended
for patients with certain conditions or diseases. Commencement and
continuing use of oral medications for onychomycosis should be closely
monitored by a physician. Long term use of oral medications for
onychomycosis is not recommended. Certain oral medications have been
associated with liver problems, with serious allergic reactions, and
with interactions with other drugs the patient might be taking.
Product Profile
Ivrea Pharmaceuticals seeks to achieve the efficacy of oral medications
and the safety of topical applications for the successful treatment of
onychomycosis. IVR 101/102 are topically applied gels which deliver
fungicidal active ingredients efficiently through the nail to the site
of the fungal infection. Ivrea Pharmaceuticals' proprietary gels have
demonstrated the ability to rapidly deliver fungus-killing
concentrations of drug through the nail. And because our products are
gel-based, they do not build-up layers of lacquer on the nail. Our gels
are also less likely to cause irritation to the surrounding skin when
compared to multiple applications of lacquers. By combining our
proprietary gels with known highly-active fungicidal ingredients, Ivrea seeks to create unique prescription products that offer an unparalleled
combination of efficacy, safety and convenience for the treatment of
onychomycosis.
|
